ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GNPX Genprex Inc

2.98
0.27 (9.96%)
Mar 28 2024 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Genprex Inc GNPX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.27 9.96% 2.98 17:24:46
Open Price Low Price High Price Close Price Prev Close
2.76 2.725 3.015 2.98 2.71
more quote information »

Recent News

Date Time Source Heading
3/22/202416:10PRNUSGenprex Announces Closing of $6.5 Million Registered Direct..
3/19/202413:24PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
3/19/202408:36PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
3/12/202409:01PRNUSGenprex Receives Notice of Patent Grant for Korean Patent..
3/06/202409:18EDGAR2Form 8-K - Current report
3/06/202408:30PRNUSGenprex Collaborators to Present Positive Preclinical Data..
2/26/202408:45EDGAR2Form 8-K - Current report
2/21/202416:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/21/202416:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/21/202416:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/14/202414:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/07/202408:15PRNUSGenprex Expands Nonclinical Programs into New Therapeutic..
2/06/202407:30PRNUSGenprex to Present at Upcoming BIO CEO & Investor Conference
2/05/202408:15EDGAR2Form 8-K - Current report
2/05/202407:30PRNUSGenprex Announces First Patient Dosed in Phase 2a Expansion..
2/02/202407:30EDGAR2Form 8-K - Current report
1/31/202409:00EDGAR2Form 8-K - Current report
1/31/202408:42PRNUSGenprex Announces 1-for-40 Reverse Stock Split Effective..
1/05/202416:17EDGAR2Form 8-K - Current report
1/05/202407:00PRNUSGenprex Provides Business Update and Outlook for 2024
12/18/202316:35EDGAR2Form 8-K - Current report
12/13/202316:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/13/202316:44EDGAR2Form 8-K - Current report
11/14/202311:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/03/202316:19EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/03/202316:16EDGAR2Form DEF 14A - Other definitive proxy statements
11/01/202307:30PRNUSGenprex to Present at BIO-Europe 2023 Conference
10/23/202317:01EDGAR2Form PRE 14A - Other preliminary proxy statements
10/23/202316:44EDGAR2Form 8-K - Current report
10/20/202307:30PRNUSGenprex to Host a Virtual Key Opinion Leader Event on..
10/04/202312:00PRNUSGenprex to Present Data on the Use of REQORSA® for the..
9/25/202316:20EDGAR2Form 8-K - Current report
9/21/202308:30GLOBEGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
9/20/202308:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
9/08/202316:20EDGAR2Form 8-K - Current report
9/07/202307:30PRNUSGenprex to Present at Upcoming September Investor Conference
9/01/202316:17EDGAR2Form 8-K - Current report
8/22/202307:30PRNUSGenprex Appoints Suzanne Thornton-Jones as Senior Vice..
8/21/202317:13EDGAR2Form 8-K/A - Current report: [Amend]
8/21/202312:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/15/202308:30EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
8/10/202307:30PRNUSGenprex Granted FDA Orphan Drug Designation (ODD) for..
7/24/202312:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
7/21/202316:15PRNUSGenprex Announces Closing of $7.5 Million Registered Direct..
7/20/202316:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
7/19/202316:06EDGAR2Form 8-K - Current report
7/19/202308:00PRNUSGenprex Announces $7.5 Million Registered Direct Offering..
7/18/202309:06EDGAR2Form 8-K - Current report
7/18/202308:37PRNUSGenprex Signs Exclusive License to Additional Diabetes..
7/14/202316:32EDGAR2Form 8-K - Current report

Your Recent History

Delayed Upgrade Clock